Product Images Alendronate Sodium

The text represents a graph showing the cumulative incidence of hip fractures in a study of FIT over a 3-year period. The study includes patients who had radiographic vertebral fractures at baseline and compares the results between placebo and alendronate sodium treatments. The x-axis of the graph is labeled as "time (months)" and the y-axis is labeled as "cumulative incidence (%)."*

This is a table presenting the results of a study on the treatment of osteoporosis in postmenopausal women using Alendronate Sodium at a dosage of 10 mg/day for three years. The table shows the increase in bone mineral density (BMD) in various areas of the body, including the lumbar spine, femoral neck, and trochanter.*

This data appears to be a table or chart displaying a change in bone mineral density (BMD) in postmenopausal women over a 2-year and 3-year study. The BMD change is shown for different areas of the body, including the lumbar spine, femoral neck, and trochanter. There is also information about the amount of sodium ingested per day, but it is unclear how this information relates to the BMD data.*

This is a study that compares the effects of Alendronate Sodium 40 mg/day versus placebo or Etidronate 400 mg/day on serum alkaline phosphatase in Paget's disease of bone. The study involved 27 individuals and presents data in a graph showing the mean % change from baseline in serum alkaline phosphatase over time (in months) for each treatment group.*

uCare Pharmaceuticals is a manufacturer of Alendronate Sodium 70mg tablets, with NDC numbers 68071-3340-4 and 63071-3340-04. The tablets come in 4-tablet blister packs and the lot numbers are 000000. The medication's expiration date is 00-00. The label warns to keep the medication out of reach of children and to store it at a controlled temperature between 59-86°F. The manufacturer suggests consulting a doctor for medical advice about side effects and that side effects can be reported to the FDA.*